38280-53-4 Usage
General Description
"(DES-PYR1)-LHRH" is a synthetic form of luteinizing hormone-releasing hormone (LHRH) that is used in the treatment of hormone-sensitive prostate cancer. It contains a modified form of LHRH called des-glycinamide-lysine prostamide pyroglutamate, which is designed to provide a longer-lasting effect than natural LHRH. This modification allows for sustained inhibition of the release of luteinizing hormone and follicle-stimulating hormone, leading to a decrease in testosterone production. As a result, it can help slow the progression of prostate cancer by reducing testosterone levels in the body. "(DES-PYR1)-LHRH" is administered as a depot injection, which gradually releases the medication over an extended period of time, making it more convenient for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 38280-53-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,2,8 and 0 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 38280-53:
(7*3)+(6*8)+(5*2)+(4*8)+(3*0)+(2*5)+(1*3)=124
124 % 10 = 4
So 38280-53-4 is a valid CAS Registry Number.
InChI:InChI=1/C50H70N16O11/c1-27(2)17-36(45(73)62-35(9-5-15-56-50(53)54)49(77)66-16-6-10-40(66)48(76)58-23-41(52)69)61-42(70)24-59-44(72)37(18-28-11-13-31(68)14-12-28)64-47(75)39(25-67)65-46(74)38(19-29-21-57-34-8-4-3-7-32(29)34)63-43(71)33(51)20-30-22-55-26-60-30/h3-4,7-8,11-14,21-22,26-27,33,35-40,57,67-68H,5-6,9-10,15-20,23-25,51H2,1-2H3,(H2,52,69)(H,55,60)(H,58,76)(H,59,72)(H,61,70)(H,62,73)(H,63,71)(H,64,75)(H,65,74)(H4,53,54,56)/t33-,35-,36-,37-,38-,39-,40-/m0/s1
38280-53-4Relevant articles and documents
Hydrolytic cleavage of pyroglutamyl-peptide Bond. V. Selective removal of pyroglutamic acid from biologically active pyroglutamylpeptides in high concentrations of aqueous methanesulfonic acid
Kobayashi, Junko,Ohki, Kazuhiro,Okimura, Keiko,Hashimoto, Tadashi,Sakura, Naoki
, p. 827 - 831 (2007/10/03)
Application of aqueous methanesulfonic acid (MSA) for selective chemical removal of pyroglutamic acid (pGlu) residue from five biologically active pyroglutamyl-peptides (pGlu-X-peptides, X=amino acid residue at position 2) was examined. Gonadotropin releasing hormone (Gn-RH), dog neuromedin U-8 (d-NMU-8), physalaemin (PH), a bradykinin potentiating peptide (BPP-5a) and neurotensin (NT) as pGlu-X-peptides were incubated in either 70% or 90% aqueous MSA at 25°C. HPLC analysis of the incubation solutions showed that the main decomposition product was H-X-peptide derived from each pGlu-X-peptide by the removal of pGlu. The results revealed that the pGlu-X peptide bond had higher susceptibility than various internal amide bonds in the five peptides examined, including the Trp-Ser bond in Gn-RH, the C-terminal Asn-NH2 in d-NMU-8, and the Asp-Pro bond in PH, whose acid susceptibility is well known. Thus, mild hydrolysis with high concentrations of aqueous MSA may be applicable to chemically selective removal of pGlu from pGlu-X-peptides for structural examinations.
